Ray has over 20 years’ market access and HEOR experience developing and delivering payer-focused materials for HTA assessments and payer negotiations. These include health economics, outcomes research, evidence synthesis and submission dossiers for global, regional, and local clients. He has worked with all major HTA bodies, such as NICE, CADTH, and ICER, as well as national and local payers (e.g., primary and secondary care). Ray also develops material for strategic planning and gap analysis, conducts burden of illness studies for HTA assessments, and supports RCT and observational study design for economic analyses. Key therapy areas include oncology, infectious disease, respiratory disease, multiple sclerosis, CVD, diabetes, and rare/orphan disease. Ray currently leads the strategy solutions team within EMC. His previous roles include principal within IQVIA Global Consulting, European HEOR director at Astellas, HEOR team leader at Boehringer Ingelheim, economic evaluation technical lead at Parexel, and head of quantitative risk assessment at Public Health England.
Ray has presented studies at international conferences and authored publications for Nature, Emerging Infectious Diseases, Journal of Economics, PharmacoEconomics, Heart, and Value in Health.